Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients

NCT ID NCT07649525

Recruiting now Disease control Sponsor: University of Leeds Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combinations based on their fitness and how well their cancer responded. The goal is to find out which treatment strategy works best for different patient groups, focusing on survival and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab, lenalidomide, dexamethasone, teclistamab, talquetamab
What this could lead to: If successful, this trial could identify better treatment strategies for older or frailer myeloma patients, potentially improving survival and quality of life without the need for a stem cell transplant.
What could go wrong: This is a large phase 3 trial, but results depend on how well patients tolerate the drug combinations. Side effects from immunotherapy and standard drugs may limit benefits for some participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty non-secretory plasma cell myeloma plasma cell leukemia plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM) PLASMA CELL LEUKEMIA (PCL)

Contacts and locations

Locations

Bristol Haematology and Oncology Centre
NOT_YET_RECRUITING

Bristol, BS2 8ED, United Kingdom
Eastbourne District General Hospital
NOT_YET_RECRUITING

Eastbourne, BN21 2UD, United Kingdom
St James University Hospital
NOT_YET_RECRUITING

Leeds, LS9 7TF, United Kingdom
The Clatterbridge Cancer Centre - Liverpool
RECRUITING

Liverpool, L7 8YA, United Kingdom
The Royal Marsden Hospital
NOT_YET_RECRUITING

London, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.